Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors--implications for early myasthenia gravis treatment.

This paper describes the preparation and in vitro evaluation of 18 newly prepared bis-quinolinium inhibitors on human recombinant acetylcholinesterase (AChE) and human plasmatic butyrylcholinesterase (BChE). Their inhibitory (IC(50)) and was compared to the chosen standards ambenonium dichloride, edrophonium chloride, BW284c51 and ethopropazine hydrochloride. One novel compound was found to be a promising inhibitor of hAChE (in nM range) and was better than edrophonium chloride or BW284c51, but was worse than ambenonium chloride. This compound also showed selectivity towards hAChE and it was confirmed as a non-competitive inhibitor of hAChE by kinetic analysis. A molecular modelling study further confirmed its binding to the peripheral active site of hAChE via apparent π-π or π-cationic interactions.

[1]  U. Brodbeck,et al.  Cholinesterases from flounder muscle. Purification and characterization of glycosyl-phosphatidylinositol-anchored and collagen-tailed forms differing in substrate specificity. , 1989, European journal of biochemistry.

[2]  B. Thanvi,et al.  Update on myasthenia gravis , 2004, Postgraduate Medical Journal.

[3]  N. Ariel,et al.  Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. , 2000, Acta crystallographica. Section D, Biological crystallography.

[4]  A. Engel,et al.  Histometric study of neuromuscular junction ultrastructure , 1972, Neurology.

[5]  N. Rose.  Autoimmune diseases. , 1981, Scientific American.

[6]  L. Dwoskin,et al.  bis-azaaromatic quaternary ammonium analogues: Ligands for α4β2* and α7* subtypes of neuronal nicotinic receptors , 2002 .

[7]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[8]  Yvain Nicolet,et al.  Crystal Structure of Human Butyrylcholinesterase and of Its Complexes with Substrate and Products* , 2003, Journal of Biological Chemistry.

[9]  A. Mamalaki,et al.  Anatomy of the antigenic structure of a large memberane autoantigen, the muscle‐type nicotinic acetylcholine receptor , 1998, Immunological reviews.

[10]  Paul R Lockman,et al.  3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the blood-brain barrier choline transporter. , 2005, Bioorganic & medicinal chemistry.

[11]  A. Goldman,et al.  Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein , 1991, Science.

[12]  Y. Pang,et al.  Novel Nerve‐Agent Antidote Design Based on Crystallographic and Mass Spectrometric Analyses of Tabun‐Conjugated Acetylcholinesterase in Complex with Antidotes , 2007, Clinical pharmacology and therapeutics.

[13]  N. Greig,et al.  Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine. , 2010, Bioorganic & medicinal chemistry.

[14]  K. Kuča,et al.  Structure-activity relationship of quaternary acetylcholinesterase inhibitors - outlook for early myasthenia gravis treatment. , 2010, Current medicinal chemistry.

[15]  F. Donati,et al.  Reversal of Neuromuscular Blockade , 1992, Anesthesiology.

[16]  D. Richman,et al.  Treatment of autoimmune myasthenia gravis , 2003, Neurology.

[17]  D. Simel,et al.  Does this patient have myasthenia gravis? , 2005, JAMA.

[18]  M. B. Laskowski,et al.  Presynaptic and postsynaptic neuromuscular effects of a specific inhibitor of acetylcholinesterase. , 1980, The Journal of pharmacology and experimental therapeutics.

[19]  D. A. Dougherty,et al.  The Cationminus signpi Interaction. , 1997, Chemical reviews.

[20]  A. Vincent,et al.  Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets , 2003, The Lancet Neurology.

[21]  V. Dohnal,et al.  Preparation and in vitro screening of symmetrical bis-isoquinolinium cholinesterase inhibitors bearing various connecting linkage--implications for early Myasthenia gravis treatment. , 2011, European journal of medicinal chemistry.

[22]  J. Massey,et al.  Autoimmune myasthenia gravis: Recommendations for treatment and immunologic modulation , 2005, Current treatment options in neurology.

[23]  M. Hill.  THE NEUROMUSCULAR JUNCTION DISORDERS , 2003, Journal of neurology, neurosurgery, and psychiatry.

[24]  C. Millard,et al.  Anticholinesterases: Medical Applications of Neurochemical Principles , 1995, Journal of neurochemistry.

[25]  B. Ibach,et al.  Acetylcholinesterase inhibition in Alzheimer's Disease. , 2004, Current pharmaceutical design.

[26]  Yuan-Ping Pang,et al.  Crystal structures of acetylcholinesterase in complex with HI-6, Ortho-7 and obidoxime: structural basis for differences in the ability to reactivate tabun conjugates. , 2006, Biochemical pharmacology.

[27]  V. Dohnal,et al.  Preparation and in vitro screening of symmetrical bispyridinium cholinesterase inhibitors bearing different connecting linkage-initial study for Myasthenia gravis implications. , 2010, Bioorganic & medicinal chemistry letters.

[28]  C. Eagle,et al.  Anaesthetic management of a patient with myasthenia gravis and tracheal stenosis , 1996, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[29]  Mahmud Tareq Hassan Khan,et al.  Cholinesterase inhibitory activities of some flavonoid derivatives and chosen xanthone and their molecular docking studies. , 2009, Chemico-biological interactions.

[30]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[31]  K. Kuča,et al.  Improvement of acetylcholinesterase-based assay for organophosphates in way of identification by reactivators. , 2008, Talanta.

[32]  David S. Goodsell,et al.  Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function , 1998 .

[33]  Hermona Soreq,et al.  Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response , 1996, Nature Medicine.

[34]  M F Sanner,et al.  Python: a programming language for software integration and development. , 1999, Journal of molecular graphics & modelling.